In this regard, the in vitro growth of several BRAF-mutated canine transitional carcinoma cell lines was not inhibited by the BRAF inhibitor vemurafenib, whereas MAPK inhibitors do so similarly to human BRAF-mutant cell lines. This evidence concerns the gene BRAF and transitional cell carcinoma.